Why the study?
Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?
Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?
Once-daily edoxaban showed similar efficacy and safety to enoxaparin for the prevention of thromboembolic events in patients undergoing total hip arthroplasty.
Answers are grounded in this paper and cite their sources.
Edoxaban matches enoxaparin for post-THA VTE prevention; confirms once-daily oral option in this RCT.
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.
No takes yet. Share an insight, caveat, or question.
Fuji et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: